MDClone

What is MDClone and who sells it?

MDClone describes its ADAMS platform as a "powerful, self-service healthcare data exploration environment" for collaboration, research and innovation (mdclone.com). ADAMS stands for Ask, Discover, Act, Measure, Share. The platform generates synthetic data meant to let teams "collaborate across teams, organizations, and even external third parties," and a generative-AI assistant called ADAMS Copilot helps with data preparation, visualization and mining. A services arm called Ask the Experts takes a data question and returns findings and recommendations within one week.

MDClone Ltd. is private and calls itself an Israeli startup in its own press release. Funding figures differ by source. A $15M round appears in a press release and $26M in BioSpace. A $63M Series C in March 2022 was led by Warburg Pincus and Viola Growth (Fierce Healthcare). Totals are $104M on Tracxn and $112M on PitchBook, and PitchBook lists about 100 employees. The Series C is the latest round on record. The newest items on its news page are a 2025 "Companies to Watch" selection and 2024 deployments. The founding year is not stated.

What does it do well?

Instead of waiting for a data extract, a team explores a cohort and shares a synthetic copy. MDClone's own documents say the synthetic data is "non-reversible" and allows analysis "independent of the IRB process." Those are vendor claims, and no independent validation of re-identification risk or of how well synthetic data preserves the signal in the original is cited.

The home page features three customer stories that the vendor selected. Intermountain Health used it for kidney disease management, with "86% of newly enrolled patients avoided hospitalizations." Sheba Medical Center used it for AI detection of intracranial hemorrhage, with lower mortality after the AI went live. Washington University used it for a cirrhosis mortality prediction model. These are vendor-selected case studies with no method attached.

What does the research say?

Three PubMed papers name the platform, and all of them used it to pull data for another question. They cover renal colic and high ambient temperature (Urolithiasis, 2024, PMID 38564058), osteoporosis documentation after hip fracture (BMC Musculoskelet Disord, 2026, PMID 41866492), and recurrent fractures in hip fracture patients (J Clin Med, 2025, PMID 41375797). None of these tests whether the platform gives accurate or safe answers. They show that researchers use it as an extraction tool.

How much does MDClone cost?

MDClone prices by demo request. The site offers a "See ADAMS in Action" form, and no pricing page exists as of October 2026. Trial and refund terms are not stated.

Who is it for?

A chief data officer at an academic medical center who wants to cut time on research data requests is the target buyer. A research analyst who has to share data with an outside collaborator is the daily user. HIPAA, SOC 2 and ISO 27001 status is not published. FDA clearance does not apply.

The verdict

Buy MDClone if you run a health system with a warehouse, a data team and a steady queue of research data requests, and a reference customer can show how the synthetic output was checked against source data. Skip it if you need independent proof that synthetic data preserves clinical signal, because the evidence today is vendor case studies and papers that use the platform without testing it.